In this study, we retrospectively investigated the outcome of NSCLC patients with EGFR mutations carrying PD-L1 TPS ≥ 50% after developing EGFR-TKI resistance with ICI therapy and explored the population that may benefit from ICI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.